IceCure Medical is excited to participate at the 2025 Indian Society of Vascular and Interventional Radiology (ISVIR) Annual Meeting in Kochi, Kerala, from February 6–9, 2025.
Visit the IceCure Booth!
IceCure’s Regional Sales Executive, Noam Sorek, and International Sales Director, Rafael Kaplan, will be on-site to discuss the benefits of our liquid nitrogen-based ProSense™ Cryoablation System for use in a wide variety of clinical applications in interventional radiology.
Cryoablation for Breast Tumors with ProSense™
Lead by IceCure Medical, the ICE3 trial on cryoablation of early-stage, low-risk breast cancer* published promising 5-year results. Published in the Annuals of Surgical Oncology by Richard Fine, MD, patients treated with ProSense cryoablation and endocrine therapy only had 97.3% recurrence free rate and 100% physician and patient satisfaction with cosmetic results. The IceCure team will be available to answer all of your questions on this innovative approach to breast cancer care.
Live ProSense Cryoablation Demos
ISVIR participants will have the opportunity to experience the power of liquid nitrogen cryoablation with ProSense. Our easy-to-use single cryoprobe system can create large lethal zones with a single point of entry. It has a good safety profile and well-established low tumor recurrence rate.
Meet our partners in India
IceCure will be exhibiting alongside our partners in India, Novomed and Edifice Medical Technologies. This is a fantastic opportunity to meet with the teams face-to-face that can support you in adding ProSense cryoablation to your practice.
Learn more about partnering with IceCure in India, from Jay Metha at Novomed:
Don’t miss this opportunity to discover the latest innovations in cryoablation and connect.
To schedule a meeting or learn more, fill out our contact form.
We look forward to seeing you at ISVIR 2025!
*The breast cancer indication for the ProSense® System is currently under review by the FDA and has not yet received marketing clearance in the US. ProSense™ is cleared for the treatment of breast cancer in the EU and other select markets. Clinical indications vary by region, please contact us for additional details.